tFold designs binding antibodies against four defined antigens
Tencent researchers generated antibodies against influenza hemagglutinin, PD-1, PD-L1 and SARS-CoV-2 RBD, followed by phage-display screening and SPR characterization. Anti-SC2RBD-H330 showed neutralization IC50 of 0.42 nM. Screening remained extensive, and some confident epitope predictions failed competition tests. The date represents initial journal publication, preceding the January 19, 2026 version of record; a tFold precursor was posted February 8, 2024.
Technology: tFold System; tFold-Ab; tFold-Ag; AlphaFold-Multimer
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Binding and competition assays on generated antibodies; RBD-antibody neutralization.
- Still unknown: Separate supplements and independent replication not assessed. First-public dates of individual journal experiments were not established by precursor version comparison.
- AI role: Generates CDR sequences and predicts complexes for structure-guided filtering.
Evidence sources: https://www.nature.com/articles/s41467-025-67361-9?error=cookies_not_supported · https://www.biorxiv.org/content/10.1101/2024.02.05.578892v1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.